|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | C12N 15/60 | |
| C12N 15/63 | |||
| A61K 48/00 | |||
| C12N 9/88 | |||
| A61K 38/51 |
| (11) | Patento numeris | 1631237 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 04776039.2 |
| Europos patento paraiškos padavimo data | 2004-05-17 | |
| (97) | Europos patento paraiškos paskelbimo data | 2006-03-08 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2016-11-30 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2004/015662 |
| Data | 2004-05-17 |
| (87) | Numeris | WO 2004/110360 |
| Data | 2004-12-23 |
| (30) | Numeris | Data | Šalis |
| 471300 P | 2003-05-16 | US | |
| 471239 P | 2003-05-16 | US | |
| 471240 P | 2003-05-16 | US | |
| 474372 P | 2003-05-29 | US |
| (72) |
GRUSKIN, Elliott, A., US
CAGGIANO, Anthony, O., US
ROY, Gargi, US
D`SOUZA, Rohini, US
|
| (73) |
Acorda Therapeutics, Inc.,
420 Saw Mill River Road, Ardsley, NY 10502,
US
|
| (54) | PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS |
| PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS |